View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 28, 2022

TFF Pharma concludes enrolment of Phase I inhaled Covid-19 treatment trial

Based on results from the trial, Union Therapeutics holds an option to licence the dry powder formulation of niclosamide.

TFF Pharmaceuticals has concluded subject enrolment in a Phase I clinical trial of a dry powder formulation of niclosamide to treat Covid-19 and other respiratory viral ailments.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A total of 40 healthy participants were enrolled in the trial. The company anticipates reporting full safety results from the trial later this quarter.

The trial comprised two phases, namely single ascending dose (SAD) and multiple ascending dose (MAD). 

In the SAD phase of the trial, healthy subjects in three arms were given single inhalation doses of 0.5, 2, and 6mg. 

Six subjects will be given active drug while two will receive a placebo.

The MAD phase consisted of 3 and 6mg doses given twice daily for 4.5 days. 

No safety concerns or issues were found by the Safety Management Committee, which recommended the use of 6mg twice daily as safe for testing in the Phase II trial.

Union Therapeutics holds an option to exclusively licence the dry powder formulation of niclosamide based on Phase I trial data.

Following licencing, the company will oversee the next phase of the therapy development.

TFF Pharmaceuticals Clinical Development head Dale Christensen said: “We believe that our formulation of niclosamide will be able to be administered using an approved inhaler and acts directly at the primary site of infection, which we hope will show acceptable efficacy in the next phase of development now that we have completed enrolment in our Phase I safety study. 

“Importantly, niclosamide targets human cell pathways rather than the SARS-CoV-2 virus itself, so it is not affected by mutations in the spike protein and could theoretically work against any emerging variant.”

An antiviral therapy, niclosamide is a SARS-CoV-2 inhibitor with potential activity against several variants of the virus.

The company plans to leverage its Thin Film Freezing technology to create the inhaled formulation of niclosamide, which can directly act on the lungs where Covid-19 infection occurs. 

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena